TuHURA Biosciences (NASDAQ:HURA) Given “Buy” Rating at HC Wainwright

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 206.12% from the company’s previous close. HC Wainwright also issued estimates for TuHURA Biosciences’ FY2025 earnings at ($0.56) EPS and FY2026 earnings at ($0.52) EPS.

TuHURA Biosciences Stock Performance

Shares of HURA stock opened at $3.92 on Friday. The company’s 50-day simple moving average is $3.68 and its two-hundred day simple moving average is $4.07. TuHURA Biosciences has a one year low of $1.80 and a one year high of $7.93.

TuHURA Biosciences (NASDAQ:HURA) last issued its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Hedge Funds Weigh In On TuHURA Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Accent Capital Management LLC bought a new position in TuHURA Biosciences in the 4th quarter worth about $29,000. TT Capital Management LLC bought a new position in TuHURA Biosciences in the 4th quarter worth about $41,000. Jefferies Financial Group Inc. bought a new position in TuHURA Biosciences in the 4th quarter worth about $54,000. Bank of America Corp DE bought a new position in TuHURA Biosciences in the 4th quarter worth about $59,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of TuHURA Biosciences in the 4th quarter worth approximately $61,000. 0.62% of the stock is currently owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.